Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
Biotech
PE dealmaking, exit counts on the rise in Q3: PitchBook
The private equity market is showing signs of recovery, with strong deal activity and lower interest rates driving optimism.
Gabrielle Masson
Oct 20, 2025 5:05pm
Boston Scientific to drop $533M to acquire Nalu Medical
Oct 20, 2025 12:04pm
2 European biotechs link to tackle neurodegenerative diseases
Oct 20, 2025 8:20am
Xoma and Lava buyout cools with lower offer
Oct 17, 2025 2:35pm
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Astellas turns down option to license Taysha gene therapy—again
Oct 17, 2025 10:50am